TC BioPharm is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease.
We have a growing team based in our Glasgow office, alongside a wide range of scientific advisors, and partner organisations.
Location: United Kingdom, Scotland, Holytown
Employees: 51-200
Founded date: 2014
Investors 3
Mentions in press and media 5
| Date | Title | Description | Source |
| 28.10.2022 | Two Aurinia execs are out — and CRISPR’s operations chi... | Robert Huizinga → According to an SEC filing, Aurinia’s EVP of research Robert Huizinga and ... | endpts.com... |
| 17.09.2020 | Immune system ‘bully boys’ square up to coronavirus crisis... | Scalable, affordable, effective. Read about TC Biopharm’s stunning progress in the Financial Times h... | ncltv.co.u... |
| 17.09.2020 | Immune system ‘bully boys’ square up to coronavirus crisis... | Scalable, affordable, effective. Read about TC Biopharm’s stunning progress in the Financial Times h... | nclim.co.u... |
| 12.12.2017 | bluebird bio and TC BioPharm Announce Strategic Collaboratio... | – Deal combines TC BioPharm’s leading gamma delta T Cell capabilities with bluebird’s proven experti... | ncltv.co.u... |
| 12.12.2017 | bluebird bio and TC BioPharm Announce Strategic Collaboratio... | – Deal combines TC BioPharm’s leading gamma delta T Cell capabilities with bluebird’s proven experti... | nclim.co.u... |